Expanding National Clinical Outcome Assessment Capacity with Train(e)d
To improve diagnosis, monitor disease progression, and evaluate treatment response, NMD4C’s Outcome Measures and Natural History (OMNH) group is building a national framework for outcome measure development and infrastructure for natural history studies, integrating patient-reported outcome measures, and expand diagnostic imaging capacity.
This work will support clinical trials, real-world evidence generation, and improved care for individuals living with NMDs.
As knowledge gaps in outcome measures assessments have become evident, MDC together with the NMD4C have developed Train(e)d, an on-demand e-learning platform designed to address gaps in evaluator training and improve the consistency of clinical assessments across Canada.
This platform is a part of NMD4C’s goal of developing resources that aim to harmonize outcome measures and promote accessible, sustainable, and validated training, thus increasing clinical capacity on a national level.
Enrollment keys are required to access our course modules. These will be provided by email within the next business day after registering.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.